

Special Issue

New Insights into Cancer Immunotherapy: From Immune Cell to Clinical Practice

Message from the Guest Editor

The landscape of cancer immunotherapy is rapidly expanding, driven by advancements in the harnessing of various immune cell types to combat cancer. This Special Issue highlights recent breakthroughs in immunotherapy, encompassing T cells, natural killer (NK) cells, dendritic cells, macrophages, myeloid-derived suppressor cells (MDSCs), and other immune components shaping anti-tumor responses. We welcome studies on engineered immune cell therapies, bispecific immune engagers, immune checkpoint modulation, and novel combination strategies for enhancing therapeutic efficacy and overcoming resistance. Additionally, contributions on tumor microenvironment interactions, mechanisms of immune evasion, and translational research connecting preclinical discoveries to clinical practice are highly encouraged. Through this Special Issue, we seek to provide comprehensive insights into the evolving field of cancer immunotherapy and its impact on patient outcomes.

Guest Editor

Dr. Xiaotong Song

Translational Medical Sciences, Texas A&M University, Bryan, TX, USA

Deadline for manuscript submissions

30 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/231602

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)